Part D IRA Round 2 Stocking Strategy:
Cash Flow, Rebate Lag & GLP-1 Inventory Math for January 2027

The 15 Round 2 Drugs and Why This Cohort Hits Independents Harder Than Round 1

Round 1 of Inflation Reduction Act drug negotiation took effect January 1, 2026 and covered ten Part D drugs: Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and the Fiasp/NovoLog insulin family. Round 1 was a meaningful change to revenue cycle workflow but most independents absorbed it without major operational disruption — the volume was concentrated in a handful of NDCs, and several Round 1 drugs (Stelara, Imbruvica) were already specialty-channel items running through limited distribution.

Round 2, effective January 1, 2027, is materially different. CMS announced the negotiated Maximum Fair Price (MFP) for 15 additional Part D drugs:

• Ozempic, Wegovy, Rybelsus — the semaglutide family, treated as a single negotiation unit
• Trelegy Ellipta — fluticasone/umeclidinium/vilanterol inhaler
• Breo Ellipta — fluticasone/vilanterol inhaler
• Janumet, Janumet XR — sitagliptin/metformin
• Tradjenta — linagliptin
• Xtandi — enzalutamide (oncology)
• Pomalyst — pomalidomide (oncology)
• Ibrance — palbociclib (oncology)
• Otezla — apremilast (immunology)
• Calquence — acalabrutinib (oncology)
• Austedo, Austedo XR — deutetrabenazine (movement disorders)
• Linzess — linaclotide (GI)
• Vraylar — cariprazine (psychiatry)

Three things separate this list from Round 1 in operational terms. First, the GLP-1s. Ozempic, Wegovy, and Rybelsus are now top-20 dispense items at most independents. A typical $4M–$8M revenue independent dispenses 800–2,000 GLP-1 scripts per month across the three products. Round 1 had nothing comparable in volume. Second, Trelegy and Breo are routine retail-channel inhalers — high-volume, low-cycle-time fills that cannot tolerate a stocking workflow that runs out on day 6 of a 30-day month. Third, Janumet and Tradjenta both sit in the diabetes care set alongside Round 1's Januvia and Farxiga; that means the diabetes shelf is now almost entirely IRA-negotiated, and a single diabetic patient may carry three or four MFP-flagged claims per month.

How the Cash Flow Actually Breaks: Acquisition vs. Reimbursement Timing

Under the Medicare Transaction Facilitator (MTF) data flow that CMS finalized for IRA implementation, the pharmacy still acquires the drug through normal wholesale channels — McKesson, Cardinal, AmerisourceBergen, or a primary GPO contract — at WAC or contracted price. There is no mechanism for the pharmacy to acquire at MFP. When the script is dispensed, the claim adjudicates at the MFP through the Part D plan, and the manufacturer separately reimburses the pharmacy for the difference between acquisition cost and MFP through the MTF.

The statutory standard for that manufacturer reimbursement is 14 days from the data transmission date. In practice, the timeline stretches because the MTF has to receive the claim data from the Part D plan, validate the claim against the MFP-eligible criteria, transmit to the manufacturer, the manufacturer issues payment, and the payment lands in the pharmacy's account. Operationally, independents should plan for a 14-to-30 day clearance window during the early months of the program, with longer tails on edge cases (rejected claims, NDC mismatches, patient eligibility variances).

The cash flow math is straightforward but unforgiving. Take a single Ozempic 1mg pen at current AWP-based acquisition (roughly $950 wholesale) versus the announced Round 2 MFP for semaglutide (in the neighborhood of $250 for the equivalent unit). Every dispense ties up roughly $700 of pharmacy capital from the moment of acquisition until the manufacturer's MTF payment clears. Multiply by 1,500 GLP-1 scripts per month, and the rolling float is approximately $1.05M of acquisition cost outstanding against $375K of immediate plan reimbursement, with $675K queued for manufacturer settlement. Even at a clean 14-day clearance, that's roughly half a month's float — which is real working capital that must be either funded out of operating cash, drawn from a line of credit, or extracted by tightening other parts of the cycle.

The Stocking Math: Why "Just Cut Inventory" Doesn't Work

The reflexive owner response to a working-capital squeeze is to cut stocking levels. With GLP-1s and inhalers in Round 2, that reflex is wrong on three fronts.

You can't substitute your way out of MFP

For semaglutide there is no therapeutic equivalent at retail that escapes MFP — Wegovy and Ozempic are both on the list, Rybelsus (oral semaglutide) is on the list, and the Mounjaro/Zepbound tirzepatide alternatives are not yet IRA-negotiated but are likely candidates for Round 3 (CMS expected to announce in early 2026 with effect Jan 2028). Steering patients to alternatives is operationally impossible at the dispense window and clinically inappropriate without prescriber involvement.

Stockouts cost more than the float they save

A patient who walks in for a 30-day Ozempic refill and gets told "we don't have it, try tomorrow" has a 25–35% probability of moving the script to a chain or mail-order — and once moved, they are unlikely to return. The lifetime value of a chronic GLP-1 patient at typical retail-pharmacy margins (post-MFP) still exceeds the float exposure of carrying their 30-day supply. Cutting stocking to manage cash is a one-month win and a multi-year revenue loss.

30-day refill cadence drives Star Ratings and preferred-network economics

The Adherence to Diabetes Medications and Adherence to Hypertension Medications measures inside the Pharmacy Quality Alliance set drive Star Ratings, which drive preferred-network status, which drives the 2027 reimbursement curve. A patient who can't get their refill on day 31 because the pharmacy is dose-rationing inventory to manage cash is an adherence point you actively lose. Multiplied across a panel, this is the kind of operational decision that quietly downgrades a pharmacy out of preferred status — which costs more, every month, than the float it preserved.

The right model is not "less inventory" — it's tighter inventory cycle. Daily replenishment tuned to actual fill velocity per NDC, paired with a manufacturer rebate-tracking ledger that lets the owner see exactly how much capital is in flight at any moment.

What the Rebate-Lag Tracking Workflow Has To Do

PioneerRx, BestRx, Liberty Software, and Computer-Rx all surface the IRA flag on a claim and capture the MFP-adjusted plan reimbursement. None of them, as of early 2026, run the post-claim manufacturer reconciliation workflow that closes the cash-flow loop. That gap is exactly where a thin custom automation layer earns its keep.

The workflow has four jobs:

1. Capture every MFP-flagged claim at adjudication with the full data set required for rebate matching: NDC, dispense quantity, days supply, patient ID (de-identified for tracking), MFP, WAC at dispense, expected manufacturer reimbursement, claim ID, and adjudication timestamp.
2. Match incoming manufacturer remittances to open claims. When the MTF transmits a payment file or the manufacturer remits via 835, parse the remittance, match by claim ID and NDC, and post the variance (expected vs. actual) to a per-NDC ledger.
3. Age unmatched claims and flag SLA breaches. Any claim outstanding beyond a configurable window (we typically set 21 days for early-program tracking, tightening to 14 days once steady-state) gets queued for manufacturer follow-up with the full data packet attached.
4. Feed a daily cash-flow projection that tells the owner: how much capital is currently floating, broken down by drug and by aging bucket; how much is overdue and at risk; how much will clear in the next 7 days based on historical clearance velocity.

That last piece — the daily working-capital projection — is what turns the IRA exposure from a black box into a managed line item. Owners who can answer the question "how much of my cash is in flight against MFP rebates today?" make smarter inventory and credit-line decisions every week.

Inventory Strategy: The Buffer Stock and JIT Replenishment Pattern

For the high-velocity Round 2 SKUs — particularly the GLP-1 family, Trelegy, and Breo — the operationally and financially correct posture for an independent is:

• Buffer stock sized to 5-7 days of fill velocity per NDC, not the 14-21 days many independents are running today. At 1,500 GLP-1 fills per month (50/day), a 6-day buffer is 300 units across the semaglutide SKUs — substantial inventory exposure but bounded.
• Twice-weekly replenishment on the highest-velocity NDCs, tied to actual fill data from the prior 7 days rather than a static reorder point. The wholesaler's order pattern shifts from weekly to twice-weekly; this typically does not increase the all-in cost of goods materially when GPO terms are honored.
• Hard-floor minimum stock on each NDC that triggers an emergency reorder regardless of the regular replenishment cycle. The hard floor protects against unexpected demand spikes (a prescriber's panel adding 30 patients in a week is a real scenario).
• Pre-pack and bin segregation for IRA-flagged inventory so dispense staff can immediately verify the MFP claim adjudicated at the right tier. Mis-dispensed NDCs (e.g., a 2mg pen against a 1mg script) on MFP claims are a manufacturer-reimbursement headache that an extra second at the bin pick eliminates.

The GLP-1 storage requirement (refrigeration for Ozempic and Wegovy in initial use; room temperature post-first-use for limited windows) does not change under MFP — the DSCSA, USP <800>, and product-specific stability requirements are independent of the negotiation program. Refer to our DSCSA Small Dispenser Deadline Countdown for the parallel compliance track that overlays IRA implementation in the same time window.

The Practical Working Capital Plan for Q3 2026 Through Q1 2027

With eight months until MFP take-effect, the planning window is open enough to do this without panic, but tight enough that the work needs to start now. The sequence we recommend to independent pharmacy owners:

Where the Off-the-Shelf Pharmacy Software Stops

Independent pharmacy management systems are the system of record and they should stay that way. The IRA gap is not a reason to migrate platforms. The gap is in the operational layer that sits on top of the PMS:

• PioneerRx — Captures the IRA flag, posts the MFP claim, exposes a basic IRA reporting view. Does not run the manufacturer remittance reconciliation, does not produce a working-capital projection, does not age unmatched claims.
• BestRx — Same. Strong on basic dispense and PBM workflows; the IRA-specific cash-flow tooling has not been a reported priority through early 2026.
• Liberty Software — Same posture. Owners have to build the reconciliation outside the PMS in Excel or a custom tool.
• Computer-Rx — Same.

None of these are deficiencies of the platforms themselves — running the post-claim manufacturer reconciliation against MTF transmission files is genuinely outside the scope of a pharmacy management system. It belongs in a thin custom automation layer that reads from the PMS and the bank/clearing data, runs the matching, and writes the cash-flow projection back to a dashboard the owner can check daily. That's the same architecture pattern we use for workflow automation engagements across DME, dental, and CPA verticals — system of record stays where it is, the operational layer handles the reconciliation, projection, and exception management.

What This Looks Like When It's Working

By the second week of January 2027 a well-prepared independent pharmacy looks like this. The owner opens a daily dashboard and sees: total MFP-flagged dispenses yesterday, total acquisition cost outstanding against MFP rebates, aging buckets (0-7 days, 8-14, 15-21, 22+), expected clearances in the next 7 days, and any claims overdue beyond SLA. The wholesaler order goes out twice a week against actual fill velocity, not a static reorder point. The line of credit is sized to absorb the rolling float with margin to spare. Every manufacturer payment that lands gets matched to its open claim within 24 hours, and any variance posts to a per-NDC reconciliation report that the owner reviews weekly.

By contrast, a pharmacy that arrives at January 2027 without the workflow looks like this. The owner notices in late January that the bank account is unexpectedly tight. They pull a manual report and discover roughly $400K in MFP rebates outstanding, with no clear visibility on which claims have cleared, which are pending, and which are overdue. They draw on the line of credit to cover payroll and Cardinal's invoice. Six weeks later, when the rebates have mostly cleared, they can see what happened in retrospect — but they spent six weeks running the business with their hands tied behind their back.

The difference between those two pictures is a thin automation layer built in the last quarter of 2026 against the existing PMS data flow.

Compliance and Data-Handling Considerations

The MTF data flow and the manufacturer-remittance reconciliation involve dispense-level data that includes patient identifiers in some implementations. A custom automation layer that handles this data needs to be built on a HIPAA-compliant footing from kickoff: BAA with the pharmacy, encrypted-at-rest and in-transit data stores, audit logging on every record access, role-based access for staff, and a documented data retention policy. We build all healthcare automation under those baseline controls; for IRA-specific implementations the additional consideration is that MTF transmission data is governed by CMS data-use guidance which adds layers around manufacturer-facing data sharing. None of this is operationally onerous if it's designed in from day one — it becomes painful only when retrofitted onto an existing pipeline that wasn't built for it.